CinFina Pharma Begins Phase 1 MAD Clinical Trial of CIN-110 for Obesity Treatment

CinFina Pharma, a company within the CinRx portfolio, has announced the commencement of the Phase 1 Multiple Ascending Dose (MAD) clinical trial for CIN-110, a new and highly selective PYY3-36 analog aimed at treating obesity. This trial will focus on assessing the safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CIN-110 in adults grappling with obesity. The initiation of this MAD trial follows a preceding Single Ascending Dose (SAD) study where CIN-110 was well-received and showed significant reductions in both caloric intake and body weight. Insights from the SAD study will guide dosing decisions for the ongoing MAD study.

Mary Bond, M.S., M.B.A., Chief Translational Science Officer of CinRx Pharma, expressed optimism about CIN-110's progression. She noted that the single-dose studies have shown excellent safety and pharmacokinetic profiles along with encouraging pharmacodynamic data. The company is excited to advance this promising asset into the next phase of clinical testing to better understand its potential as a safe and effective obesity treatment for both physicians and their patients.

CIN-110, as a potent and highly selective PYY3-36 analog, exhibits an extended half-life and has the potential to be both durable and well-tolerated. Importantly, it does not induce the significant nausea and vomiting often seen in earlier PYY-centric therapies. PYY3-36 is a natural hormone released by endocrine L-cells in the gut in response to food intake—especially fat. It serves as a selective agonist of the neuropeptide Y2 receptor (Y2R), effectively reducing appetite and food intake.

The Phase 1 MAD study will be conducted as a randomized, placebo-controlled clinical trial. It aims to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of subcutaneously (SC) administered CIN-110 in obese adults over a 12-week period. Participants will include males and females aged 18-55 with a body mass index (BMI) ranging from 30.0 to 44.9 kg/m2. The study will feature multiple cohorts, each consisting of 12 subjects randomized in a 3:1 ratio to receive either SC CIN-110 or a placebo.

CinFina Pharma is committed to broadening the treatment landscape for obesity and its associated health conditions. The company is developing a pipeline of therapeutic candidates designed to be safe, tolerable, and effective in helping individuals lose weight and maintain weight loss, ultimately improving overall health. CinFina's four therapeutic candidates are naturally occurring peptides engineered for prolonged activity to regulate insulin secretion and feelings of satiety.

CinRx Pharma, the parent company, is a biotech firm that progresses a varied portfolio of high-impact medications through clinical development using a distinctive hub-and-spoke business model. CinRx combines financing with efficient development processes, managing each therapeutic candidate within its portfolio through a central infrastructure and operating team. The company's current focus areas include metabolic, gastrointestinal, and oncological diseases. CinRx's unique approach involves an asset selection process that is independent of therapeutic area and leverages strategic CRO partnerships and insights gained from extensive development programs. This enables CinRx to identify, fund, and accelerate promising drugs that have the potential to significantly improve patients' quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!